Agharkar Institute Develops Biodegradable Nanocarrier for Dual Gene Silencing in Breast Cancer — Precision Nanomedicine

Overview Scientists from the Agharkar Research Institute (ARI) , an autonomous institute under the Department of Science & Technology (DST) , have created a biodegradable nanocarrier that can silence two major cancer‑survival genes in breast cancer. The platform uses nanomedicine to deliver therapeutic RNA molecules directly to tumour cells, reducing systemic toxicity. Key Developments Construction of mesoporous silica nanoparticles (MSNs) that are fully biodegradable. Functionalisation with a MUC1 aptamer and protamine biopolymer to achieve tumour‑specific uptake. Simultaneous loading of siRNA against the anti‑apoptotic genes MCL‑1 and Survivin – a dual gene silencing approach. Glutathione‑responsive release mechanism that triggers payload delivery inside the tumour micro‑environment. In‑vivo validation in SCID mice showing high tumour accumulation and minimal systemic toxicity. Important Facts The nanocarrier achieved >70 % knock‑down of both MCL‑1 and Survivin in MCF‑7 breast cancer cells, leading to marked apoptosis. In SCID mouse models, tumour growth was reduced by more than 60 % compared with untreated controls. Histological analysis revealed no significant damage to major organs, indicating good safety profile. The study is published in Advanced Healthcare Materials (2026) and is funded by the DST, reflecting government support for high‑impact biotech research. UPSC Relevance The development illustrates the intersection of nanomedicine and gene‑silencing technologies, both listed under GS3 topics on biotechnology and health. It showcases how government‑funded research institutes like ARI translate basic science into potential clinical solutions, a point often examined in questions on science policy, public‑private partnership, and health‑care innovation. Understanding terms such as mesoporous silica nanoparticles and siRNA helps candidates answer questions on emerging therapeutic modalities and their regulatory implications. Way Forward Further work should focus on scaling up the nanocarrier production, conducting toxicology studies in larger animal models, and seeking clinical trial approval. Policy‑wise, the DST may consider creating dedicated funding streams for translational nanomedicine, encouraging collaborations between research institutes, biotech firms, and hospitals. Strengthening regulatory frameworks for nanotechnology‑based therapeutics will ensure safe and rapid deployment of such precision medicines in India.